KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) Other Operating Expenses: 2017-2025

Historic Other Operating Expenses for Moderna (MRNA) over the last 5 years, with Sep 2025 value amounting to $207.0 million.

  • Moderna's Other Operating Expenses fell 59.73% to $207.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year decrease of 30.17%. This contributed to the annual value of $1.5 billion for FY2024, which is 68.80% down from last year.
  • As of Q3 2025, Moderna's Other Operating Expenses stood at $207.0 million, which was up 73.95% from $119.0 million recorded in Q2 2025.
  • In the past 5 years, Moderna's Other Operating Expenses registered a high of $2.2 billion during Q3 2023, and its lowest value of $90.0 million during Q1 2025.
  • Its 3-year average for Other Operating Expenses is $597.5 million, with a median of $514.0 million in 2024.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first soared by 11,800.00% in 2021, then plummeted by 87.88% in 2024.
  • Moderna's Other Operating Expenses (Quarterly) stood at $952.0 million in 2021, then skyrocketed by 101.47% to $1.9 billion in 2022, then crashed by 51.56% to $929.0 million in 2023, then declined by 20.45% to $739.0 million in 2024, then crashed by 59.73% to $207.0 million in 2025.
  • Its last three reported values are $207.0 million in Q3 2025, $119.0 million for Q2 2025, and $90.0 million during Q1 2025.